Market Overview

UPDATE: Catamaran Q3 Profit Down 19%

UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition
Catamaran To acquire Salveo Specialty Pharmacy For $260M In Cash
Update: Catamaran's Acquisition Of Salveo Specialty Pharmacy (Seeking Alpha)

Catamaran (NASDAQ: CTRX) reported a 19% drop in its third-quarter profit.

Catamaran's quarterly net income declined to $20.5 million, or $0.10 per share, versus $25.3 million, or $0.20 per share, in the year-ago period.

Its revenue surged to $3.2 billion from $1.3 billion.

Catamaran shares closed at $47.16 yesterday.

Posted-In: profitEarnings News


Related Articles (CTRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters